SCHEMBL22844609

SCHEMBL22844609

CC/C=C\C/C=C\C=N/COC(=O)OC(C)C(C)(C)C

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 2/20 0.35
NR1I2 O75469 2/20 0.35
PTGS2 P35354 2/20 0.35
PGR P06401 1/20 0.35
PDE4D Q08499 1/20 0.35
ALDH1A1 P00352 7/20 0.33
OXER1 Q8TDS5 5/20 0.33
MAPT P10636 4/20 0.33
CYP19A1 P11511 4/20 0.33
PPARA Q07869 3/20 0.33
PPARG P37231 3/20 0.33
RXRA P19793 2/20 0.33
CYP3A4 P08684 2/20 0.33
ALOX15 P16050 2/20 0.33
HSD17B10 Q99714 2/20 0.33
TDP1 Q9NUW8 2/20 0.33
FFAR1 O14842 2/20 0.33
TSHR P16473 1/20 0.33
CNR1 P21554 1/20 0.33
CNR2 P34972 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22844620 0.86 ALDH1A1 (0.38) ADORA3NR1I2PTGS2PGRPDE4D
SCHEMBL22844508 0.86 ADORA3 (0.36) ADORA3NR1I2PTGS2PGRPDE4D
SCHEMBL22844600 0.81 ADORA3 (0.38) ADORA3NR1I2PTGS2PGRPDE4D
SCHEMBL6896756 0.80 PTGS1 (0.40) ADORA3NR1I2PTGS2PGRPDE4D
SCHEMBL10087817 0.76 ALDH1A1 (0.48) ADORA3NR1I2PTGS2PGRPDE4D
SCHEMBL17132403 0.76 ALDH1A1 (0.48) ADORA3NR1I2PTGS2PGRPDE4D
SCHEMBL20260606 0.75 ALDH1A1 (0.33) ADORA3NR1I2PTGS2PGRPDE4D
SCHEMBL20697507 0.72 ALDH1A1 (0.33) ADORA3NR1I2PTGS2PGRPDE4D
SCHEMBL15483679 0.68 MGLL (0.46) ALDH1A1CNR1CNR2
SCHEMBL19500212 0.68 ALDH1A1 (0.50) ALDH1A1ALOX15HSD17B10GRM1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11518745-B2 Heterocyclic compounds for the treatment of neurological and psychological disorders ALKERMES PHARMA IRELAND LIMITED (IE) 2022-12-06 US disclosed
US-20200407320-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT 2020-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200407320-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS GABBR1, GABBR2, GABRE ADORA3 3086/4885NR1I2 277/4885PTGS2 2525/4885
US-11518745-B2 Heterocyclic compounds for the treatment of neurological and psychological disorders GABBR1, GABBR2, GABRE ADORA3 3086/4885NR1I2 277/4885PTGS2 2525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.